NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Newly Diagnosed, Primary Breast Cancer
Interventions: DRUG: BKM120|DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: BKM120 Placebo
Sponsor: Novartis Pharmaceuticals
Collaborators: Breast International Group|German Breast Group|SOLTI Breast Cancer Research Group